


POLY MEDICURE LIMITED

Regd. Office: First Floor, 11, Sans Nagar East of Kirti, New Delhi - 110 005
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH, 2010

Sr. No.	Particulars	(Rs. in lacs)			
		Standalone Year ended 31st March		Consolidated Year Ended 31st March	
		2010 (Audited)	2009 (Audited)	2010 (Audited)	2009 (Audited)
	Gross Sales/Income from operations	13766.03	11383.96	13884.63	11484.96
	Less-Excise Duty	165.57	161.60	165.57	161.60
	(a) Net Sales/Income from operations	13600.46	11222.35	13719.08	11222.36
	(b) Other Operating Income	0.00	0.00	0.00	0.00
	Total Income	13600.46	11222.35	13719.08	11222.36
2	Expenditure				
	a. (Increase)/Decrease in stock in trade and work in progress	(40.33)	(48.91)	(46.23)	(48.91)
	b. Consumption of Raw materials	5183.79	4419.62	5031.44	4419.62
	c. Purchase of traded goods	106.56	137.91	103.72	137.91
	d. Employee Cost	3153.38	1721.98	2203.69	1721.98
	e. Depreciation	706.99	646.40	783.20	671.76
	f. Other Expenditure	3326.66	3265.19	3380.97	3270.35
	g. Total	11417.35	10142.19	11662.79	10172.71
3	Profit from Operations before Other Income, Interest & Exceptional Items	2183.31	1080.16	2056.29	1049.64
4	Other Income	52.90	64.48	52.90	64.48
4A	Share of profits of Associate				
5	Profit before Interest & Exceptional Items	2236.21	1144.64	2109.19	1114.12
6	Interest & Finance Charges	412.95	480.21	413.50	480.21
7	Profit after Interest but before Exceptional Items	1823.26	664.43	1754.52	660.42
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit/Loss from Ordinary activities before Tax	1823.26	664.43	1754.52	660.42
10	Tax Expenses				
	-Current Tax	309.80	75.28	309.80	74.82
	-Prior period tax	(15.70)	(22.04)	(15.70)	(22.04)
	-Deferred Tax	64.19	85.92	64.10	85.92
	-Fringe Benefits Tax	0.00	8.00	0.00	8.00
	-Credit for Minimum Alternative Tax (MAT)	(177.95)	(75.28)	(177.95)	(74.82)
	Net Profit/Loss from Ordinary Activities after Tax	1642.94	594.55	1574.21	588.53
11	Extraordinary Items	0.00	0.00	0.00	0.00
12	Add Loss attributable to minority interest				
		1642.94	592.55	1579.93	596.16
13	Net Profit/Loss for the period				
14	Paid up Equity Share Capital (Face value Rs. 10/- per Share)	1101.25	550.63	1101.25	550.63
15	Reserves excluding Revaluation Reserve	4882.84	4088.39	4945.69	4246.57
16	Earning Per Share-Basic & Diluted (Rs.)- Pre Bonus	29.84	10.76	28.70	10.85
	Earning Per Share-Basic & Diluted (Rs.)- Post Bonus	1* 92	5.38	14.35	5.42
17	Public shareholding				
	-No. of Shares	5691688	2853894	5691688	2853894
	-Percentage of Shareholding	52.19%	51.83%	52.19%	51.83%
18	Promoters and promoters group shareholding				
a)	Pledged / Encumbered				
	- Number of shares	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the Company)				
b)	Non-encumbered				
	- Number of shares	5214562	2652356	5214562	2652356
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the Company)	47.81%	48.17%	47.81%	48.17%

- Notes:**
- The Company is primarily engaged in a business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI
 - The Board of Directors have recommended a dividend of Rs. 2.50 per equity share of Rs. 10 each, subject to approval of shareholders.
 - During the quarter ended 31st March, 2010, the company has issued Bonus shares in the proportion of 1:1 aggregating to 5506250 equity shares of Rs. 10 each to the existing shareholders of the company and allotted 5460000 equity shares and allotment of 106250 equity shares is pending due to non receipt of approval from Bombay Stock Exchange. The post bonus EPS figures for the year ended 31st March, 2009 have been reworked to give effect to the allotment of bonus shares as required by AS-20 "Earnings per share"
 - The consolidated Financial Statement has been prepared in accordance with AS- 21 "Consolidated Financial Statements" and AS-23 "Accounting for investment in Associates in Consolidated financial Statements"
 - The Company received one investor complaint during the quarter, which was resolved. There was no pending complaint either at the beginning or end of the quarter ended 31st March, 2010.
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 17th May, 2010.
 - The figures for the corresponding year have been restated, wherever necessary, to make them comparable



Himanshu Baid
 Managing Director

Place: New Delhi
 Date: 17.05.2010